The medical weight-loss provider landscape

From telehealth-only platforms to employer benefit programs, the options for medically supervised weight loss have multiplied fast. Here's how to read the field and what to ask before you sign up. lower dB covers multiple provider categories and accepts no payment for editorial placement. This article does not endorse any specific program, platform, or product. Its purpose is to give you the vocabulary and the questions you need to evaluate options on your own terms.

Telehealth-only platforms

Telehealth weight-loss platforms deliver care entirely online, often with a fast onboarding process. The typical model: you complete an intake questionnaire, a prescriber reviews it, and medication is shipped to your door. For patients in areas with few obesity medicine specialists, this kind of access can matter. The questions worth asking are about what happens after that first prescription. How much time does a prescriber actually spend reviewing your case? Is follow-up built into the program, or do you have to request it? Are the prescribers board-certified in obesity medicine, or are they general practitioners working across many specialties? Regulatory context matters here. In March 2026, the FDA issued warning letters to 30 telehealth companies for making false or misleading claims about compounded GLP-1 products. That enforcement action doesn't mean all telehealth platforms are problematic, but it does mean the category has attracted providers whose marketing has outpaced their clinical standards.

Employer benefit programs

Some employers now offer weight-loss coverage or navigation services as part of their health benefits, often through a contracted vendor. These programs typically involve an app-based coaching component, sometimes with access to prescribers through a partner network. Employer subsidies can reduce out-of-pocket costs, and integration with existing benefits can simplify the administrative side of care. But what's actually included varies widely. Before assuming your employer benefit constitutes medical care, ask whether the program includes clinical oversight or primarily behavioral coaching, whether medication management is included or requires a separate provider, and how your health data is shared with your employer or its vendors.

Clinical hybrid models

Clinical hybrid programs combine in-person visits with telehealth follow-up. They're often anchored at a hospital system, academic medical center, or an obesity medicine practice. A typical model might involve an initial in-person evaluation followed by ongoing monitoring through a mix of in-person and virtual appointments, with a multidisciplinary team that may include a physician, a registered dietitian, and a behavioral health provider. This structure most closely aligns with the Obesity Medicine Association's standards, which call for comprehensive assessment of weight history, nutrition, behavior, and long-term treatment planning. That doesn't make every hybrid program excellent, but the structure creates more opportunities for that kind of care. Questions worth asking: Does the program have a defined protocol for patients who plateau or experience side effects? Are surgical options discussed when they're clinically appropriate?

Direct-to-consumer subscription programs

Direct-to-consumer programs bundle a prescription, or the medication itself, with coaching content delivered through a monthly subscription. They're often marketed heavily through social media, and price transparency is sometimes a genuine advantage over more opaque clinical billing. The signals to watch are structural. Does the subscription model create pressure to continue medication regardless of whether it's still clinically appropriate? Is a prescriber reachable if something goes wrong between shipments? What happens to your care if you cancel or need to pause? Some subscription programs have built their model around compounded medications, a category that carries its own set of considerations, addressed in the next section.

Compounded drugs are medications prepared by a compounding pharmacy rather than manufactured by the original drug maker. They are not FDA-approved and do not undergo FDA review for safety, effectiveness, or quality before being marketed. Less is independently verified about a given compounded product than about an FDA-approved drug. Compounded GLP-1 medications can be appropriate in specific clinical circumstances, for example during a documented drug shortage, or when a patient requires a formulation that isn't commercially available. The FDA is explicit that compounded GLP-1 drugs should only be used when a patient's medical needs cannot be met by an FDA-approved drug. They are not interchangeable with brand-name versions. The FDA has received reports of adverse events linked to compounded semaglutide and tirzepatide, including dosing errors and hospitalizations. Some of these events involved products that were mislabeled, improperly stored, or incorrectly dosed. Some subscription programs built their model around compounded medications during a period of documented drug shortage. The end of a shortage period, or a shift in FDA enforcement posture, can affect the availability and legality of those products, sometimes quickly. Patients who enrolled based on access to a compounded medication may find the terms of that program change. If you are currently taking or considering a compounded GLP-1, ask your prescriber directly: why is a compounded version the right choice for me, given my clinical situation? A prescriber who can answer that question clearly is a meaningful signal.

The four categories above describe structure. The signals below help you evaluate what's actually inside that structure, regardless of which category a provider falls into.

Signs of a clinically serious program

Prescribers are identifiable, credentialed, and reachable

Intake includes a meaningful medical history, not just a BMI calculation

The program has a defined protocol for managing side effects

Follow-up is scheduled, not just available on request

Non-medication options and long-term maintenance are part of the conversation

Pricing is transparent and not contingent on continuing a specific medication

Signs of an access funnel

Onboarding takes under five minutes with no clinical review

Marketing emphasizes speed of prescription over quality of care

Compounded medications are described as equivalent to brand-name products

There is no clear path to a human clinician if something goes wrong

The program becomes unresponsive or disappears if you stop paying

Neither list is exhaustive, and no single signal is definitive. But patterns matter.

These questions apply whether you're evaluating a telehealth platform, a hybrid clinic, or an employer benefit program.

On prescribing standards

What criteria do you use to determine whether I'm a candidate for medication?

Are you following established clinical guidelines, such as the Obesity Medicine Association's Obesity Algorithm?

If I'm prescribed a compounded medication, why is that the right choice for me specifically?

On monitoring

How often will someone review my labs, weight, and side effects?

What happens if I have an adverse reaction between scheduled check-ins?

Who is responsible for my care if my prescriber leaves the platform?

On clinical oversight

Is there a physician, nurse practitioner, or PA who will actually review my case, or is intake automated?

Does this program coordinate with my primary care provider?

What is your protocol if medication alone isn't producing results?

On the business model

Is my prescription tied to a subscription I have to maintain?

What happens to my care if I need to pause or stop?

Are you receiving any financial incentive to prescribe a specific product?

A program that can't answer these questions, or that treats them as unusual to ask, is telling you something.

Provider quality varies within every category. This framework identifies questions, not verdicts. The regulatory environment for compounded GLP-1 medications is actively evolving. Patients should verify current FDA guidance at the time they're making decisions, because the rules can shift between when an article is published and when you're reading it. lower dB does not have visibility into any program's internal clinical protocols. The signals described here are observable proxies. They are not audits, and they are not guarantees. This article is not a substitute for a conversation with a clinician who knows your full medical history.